Surface Ophthalmics begins phase 2 trial in chronic dry eye
The first patient has been dosed in a phase 2 clinical trial investigating SURF-100 for the treatment of chronic dry eye disease, according to a press release from Surface Ophthalmics.
The head-to-head study is evaluating SURF-100 (mycophenolate sodium and betamethasone sodium phosphate in Klarity vehicle) against Xiidra (lifitegrast ophthalmic solution 5%, Novartis) and Restasis (cyclosporine ophthalmic emulsion 0.05%, Allergan).
The study aims to enroll about 300 patients. The primary endpoint is statistically significant symptom improvement between the study arms on the University of North Carolina Dry Eye Management Scale at day 84, the release said.
“By having SURF-100 go head-to-head with the leading marketed therapies, we hope to demonstrate clear advantages in both efficacy and, perhaps even more importantly, patient comfort and tolerability,” Kamran Hosseini, MD, PhD, president and CEO of Surface Ophthalmics, said in the release.
SURF-100 uses a “new and differentiated mechanism of action by combining mycophenolate sodium and betamethasone sodium phosphate” in the Klarity diluent, the release said.
Read more about